Docirbrutinib not checked
Carna Biosciences, Inc. · AS-1763
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- Blocks BTK, an enzyme B cells (a type of immune cell) need to grow and work. Used against some blood cancers and immune diseases.-brutinib: Bruton's tyrosine kinase inhibitors WHO name stem
- Tested for
- B-cell Malignancy, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma
- Main trialPhase 1
- “This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 (docirbrutinib) in patients with CLL/SLL or B-cell NHL who have failed or are intolerant to ≥2 lines of systemic therapy.”In the company’s words, NCT05602363 on ClinicalTrials.gov
- Other names
- AS-1763
Other drugs for B-cell Malignancy
- IbrutinibJohnson & Johnson (Janssen) · Phase 3
- AcalabrutinibAstraZeneca · Phase 3
- PirtobrutinibEli Lilly · Phase 3
- MesutoclaxBeijing InnoCare Pharma Tech Co., Ltd. · Phase 3
- SonrotoclaxBeOne Medicines (BeiGene) · Phase 3
- ZanubrutinibBeOne Medicines (BeiGene) · Phase 3
Coming up1
- Sep 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | Sep 2027 | AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026